Welcome to our dedicated page for Purple Biotech news (Ticker: PPBT), a resource for investors and traders seeking the latest updates and insights on Purple Biotech stock.
Purple Biotech Ltd. develops oncology immunotherapies as a clinical-stage biotechnology company with American depositary shares traded under PPBT. Its recurring updates center on CAPTN-3, a platform of capped or masked tri-specific antibodies designed to target tumor-associated antigens while engaging both T cells and NK cells in the tumor microenvironment.
Company news commonly covers preclinical data, toxicology and manufacturing work for IM1240, the 5T4-targeting lead CAPTN-3 antibody, and IM1305, the TROP2-targeting development candidate. Other recurring themes include oncology research collaborations, scientific advisory activity, financial results, ADR and capital-structure actions, Nasdaq listing compliance, and governance updates.
Purple Biotech (NASDAQ/TASE: PPBT) announced the initiation of the Phase 2 study for CM24, a monoclonal antibody targeting pancreatic cancer. This decision follows positive interim Phase 1b data, showing confirmed response rates and a favorable safety profile. The study will prioritize pancreatic ductal adenocarcinoma (PDAC) in collaboration with Bristol Myers Squibb, allowing for an increased number of participants and an accelerated timeline to complete the trial by 2023. This advancement is expected to extend Purple Biotech's cash runway through 2024.
Purple Biotech, listed as PPBT, reported Q1 2022 financial results, highlighting a net loss of $7.3 million, or $0.41 per ADS, compared to a loss of $6.6 million, or $0.38 per ADS, in Q1 2021. Research and Development expenses increased by 22% to $6.0 million, primarily due to CMC costs. However, Sales, General, and Administrative expenses decreased to $1.4 million. The company had $42.2 million in cash and equivalents at the end of Q1. Clinical advancements include completing enrollment for NT219 and initiating expansion arms for CM24.
Purple Biotech (NASDAQ/TASE: PPBT) has reported promising safety and efficacy results for CM24, a first-in-class monoclonal antibody, in combination with Opdivo® (nivolumab) for treating advanced solid tumors, including pancreatic cancer (PDAC). In a Phase 1b study presented at the AACR 2022 Annual Meeting, none of the 11 patients experienced dose-limiting toxicities. The treatment yielded one confirmed partial response and three stable disease results, indicating a 36% disease control rate. Pharmacokinetics showed dose-proportional exposure, paving the way for further clinical development.
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) reported its financial results for 2021, highlighting significant advancements in its oncology pipeline. The company is currently conducting Phase 1/2 trials for NT219 and CM24, with encouraging preliminary data. Financially, Purple Biotech experienced a net loss of $18.5 million, or $1.05 per share, a decrease from a net loss of $28 million in 2020. Cash reserves totaled $47.4 million, providing a runway into 2024. However, the discontinuation of Consensi, due to low revenue prospects, impacted 2021 results, reporting a loss of $0.6 million from discontinued operations.
Purple Biotech (NASDAQ: PPBT) reported a successful 2021, laying a foundation for future growth in cancer therapies. CEO Isaac Israel highlighted advancements in their clinical pipeline, especially with lead assets CM24 and NT219, which are poised for significant data readouts in 2022. The company maintains a robust financial position with $47.5 million in cash reserves. Collaborations with Bristol Myers-Squibb and The University of Texas MD Anderson Cancer Center enhance their development strategy. Overall, 2022 is projected to be a pivotal year for Purple Biotech as they continue progressing in oncology.
Purple Biotech announced the appointment of Ori Hershkovitz to its Board of Directors, aiming to leverage his extensive experience in life sciences investment. Hershkovitz has a successful history in managing substantial healthcare assets, and he expressed enthusiasm for the company’s oncology pipeline, which includes NT219 and CM24. These therapies are designed to target tumor immune evasion and drug resistance, promising potential benefits for cancer patients. The leadership change is expected to enhance corporate growth initiatives and shareholder value.
Purple Biotech announced the appointment of Fabien Sebille, Ph.D., as its Chief Business Officer. Dr. Sebille, with over 15 years in the biotechnology sector and a proven track record in oncology licensing deals, will lead the company’s business development. His experience includes senior roles at Debiopharm and co-founding TcLand Expression. The appointment aims to enhance strategic partnerships and advance Purple Biotech’s oncology pipeline, notably CM24 and NT219. The company is in a strong financial position and focused on driving long-term shareholder value.
Purple Biotech (NASDAQ/TASE: PPBT) announced the initiation of Part 2 of its Phase 1/2 clinical trial for NT219, a dual inhibitor targeting IRS1/2 and STAT3, in combination with cetuximab for treating recurrent or metastatic squamous cell carcinoma of the head and neck or colorectal adenocarcinoma. Part 1 has progressed well, with good safety and promising efficacy signals. Initial data support expanding the study, with further efficacy results expected in mid-2022, and potential new indications anticipated in the latter half of 2022.
Purple Biotech (NASDAQ/TASE: PPBT), a clinical-stage company focused on innovative cancer therapies, will present a corporate overview at the Jefferies London Healthcare Conference on November 17, 2021, at 12:20 pm GMT. The conference runs from November 16-19, 2021, with opportunities for one-on-one meetings. Purple Biotech is advancing therapies to overcome tumor immune evasion and drug resistance, including NT219 and CM24, which target various cancer indications. A replay of the presentation will be available on the company’s website.
Purple Biotech (NASDAQ/TASE: PPBT) has announced the expansion of its research collaboration with The University of Texas MD Anderson Cancer Center to assess the efficacy of NT219 combined with immuno-oncology agents. NT219, a dual inhibitor targeting IRS1/2 and STAT3, has shown promise in overcoming treatment resistance in preclinical studies. This collaboration aims to translate these findings into clinical applications, potentially converting resistant tumors into responsive ones. Positive initial clinical data from NT219 monotherapy was also presented at ASCO 2021, further supporting its advancement.